Global Coronary Stents Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016

29 Jul 2010 • by Natalie Aster

GlobalData’s new report, “Global Coronary Stents Equipment Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016” provides key data, information and analysis on the global coronary stents market. The report provides market landscape, competitive landscape and market trends information the coronary stents market. The report provides comprehensive information on the key trends affecting the market, and key analytical content on the market dynamics. The report also reviews the competitive landscape, key pipeline products and technology offerings. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

The Global Coronary Stents Market is Forecast to Exceed $6 Billion in 2016 Growing at a CAGR of 2.4% from 2009

The global coronary stents market was valued at $5.4 billion in 2009 and is forecast to reach $6.5 billion in 2016 after growing at a Compound Annual Growth Rate (CAGR) of 2.5% from 2009-2016. The growth in the market is primarily being driven by the increase in the elderly population and obesity rates, advances in technology (the emergence of bio absorbable stents and newer drugs, for example) and rising patient awareness. Due to growing appeal of less invasive percutaneous coronary intervention and the introduction of drug-eluting stents (DES), there has been a rapid increase in the coronary stents market in the past few years.

The Drug Eluting Stents Segment is the Largest and Fastest Growing Segment in the Coronary Stents Market

The DES segment continues to lead the global coronary stent market, with a contribution of 83% towards it in 2009. The global drug eluting stents segment is expected to reach $5.6 billion in 2016 after growing at a CAGR of 3% from 2009-2016.The decrease of in-stent restenosis by DES as compared to bare metal stents (BMS) and the increasing demand for minimally invasive procedures is driving the growth of the DES market. DES cause a reduction in complications and the expense of repeat procedures, so it is the safe and preferred choice for the surgeons. Another factor that will drive the DES market is the launch of bio-absorbable stents and stents with newer drugs.

The US Remains the Largest Coronary Stents Market Driven by Increasing Number of Angioplasty Procedures

The US coronary stents market is expected to reach $2.3 billion in 2016, growing at a CAGR of 1.9% from 2009-2016. The DES segment is the largest in the US valued at $1,794.6m in 2009 followed by BMS market which was valued at $256m in 2009 The BMS segment registered a negative growth rate of 13% during the period 2002-2009 due to the entry of DES in the year 2003. Due to the higher number of angioplasty procedures as a result of increasing coronary heart disease incidence and the greater penetration and existence of well-established players, US remain the largest coronary stents market. The coronary stent market in the US is going to be driven by increased penetration of DES and next generation stents, such as bio-degradable stents, in the future.

Technological Advances and Increasing Incidence of Obesity Rates and Coronary Heart Disease to Drive the Market

Coronary heart disease is the major reason for large number of deaths globally, and is expected to result in 14.2% of all deaths by 2030. The disability-adjusted life years (DALYs) for coronary heart disease are estimated to increase to nearly 82 million globally in 2020 from 47 million DALYs in 1990. Also, the obesity rate has increased globally over the past few decades. Currently more than one billion adults are overweight worldwide, which is a major contributor to coronary heart disease. This increase in incidence obesity rates and rising patient awareness will led to a strong demand for percutaneous procedures and is expected to drive the coronary stents markets.

The products with technologies like diamond carbon coating, platinum enriched stainless steel stents, completely bio-absorbable stents and antibody coated or gene therapy stents are under development. These are expected to be more efficacious, safe and bio-compatible compared to the currently marketed products and are expected to drive the coronary stents market.

Boston Scientific, Abbott Laboratories and Cordis Dominate Global Drug Eluting Stents Market

The market share leader for the drug eluting stent market is Boston Scientific with 38% of the market in 2009. Boston Scientific’s largest selling DES, the Taxus stent, has strong demand in the coronary stents market due to competitive pricing. The pricing of TAXUS in accordance with the reimbursement agencies and surgeons has essentially made it easier for surgeons to shift their preferences from Cypher (Cordis) to Taxus (Boston). Abbott is the second largest company in the DES market, with a share of 27%. Abbott's new DES Xience V has shown strong growth in the coronary stents market. Clinical trials have shown Xience V to be safer and more reliable for treating clogged heart arteries than its competition. In one clinical trial, Xience V demonstrated to be clinically superior to its competitor Boston Scientific's Taxus stent. Medtronic had 13% of the market in 2009. The approval of Endeavor in early 2008 resulted in increase in Medtronic’s share in the DES market.

About GlobalData

GlobalData is an industry analysis specialist company providing business information products and services.

Our highly qualified team of Analysts, Researchers, and Solution Consultants use proprietary data sources and various tools and techniques to gather, analyze and represent the latest and the most reliable information essential for businesses to sustain a competitive edge.